MX2019002673A - Composiciones y metodos para tratar demencia. - Google Patents

Composiciones y metodos para tratar demencia.

Info

Publication number
MX2019002673A
MX2019002673A MX2019002673A MX2019002673A MX2019002673A MX 2019002673 A MX2019002673 A MX 2019002673A MX 2019002673 A MX2019002673 A MX 2019002673A MX 2019002673 A MX2019002673 A MX 2019002673A MX 2019002673 A MX2019002673 A MX 2019002673A
Authority
MX
Mexico
Prior art keywords
compositions
treating dementia
dementia
treating
kits
Prior art date
Application number
MX2019002673A
Other languages
English (en)
Inventor
Hoffman Steven
Original Assignee
Hoffman Steven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman Steven filed Critical Hoffman Steven
Publication of MX2019002673A publication Critical patent/MX2019002673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a métodos, composiciones, y equipos para el tratamiento de demencia.
MX2019002673A 2016-09-12 2017-09-08 Composiciones y metodos para tratar demencia. MX2019002673A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US201762507531P 2017-05-17 2017-05-17
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Publications (1)

Publication Number Publication Date
MX2019002673A true MX2019002673A (es) 2019-07-04

Family

ID=59901615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002673A MX2019002673A (es) 2016-09-12 2017-09-08 Composiciones y metodos para tratar demencia.

Country Status (12)

Country Link
US (1) US10300077B2 (es)
EP (1) EP3509639A1 (es)
JP (1) JP2019526612A (es)
KR (1) KR20190072521A (es)
CN (2) CN114796236A (es)
AU (1) AU2017322332A1 (es)
BR (1) BR112019004540A2 (es)
CA (1) CA3036511A1 (es)
IL (1) IL265255A (es)
MX (1) MX2019002673A (es)
PH (1) PH12019500479A1 (es)
WO (1) WO2018049141A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952374A (en) 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
EP1865955A4 (en) * 2005-03-25 2009-04-15 Merck & Co Inc TREATMENT OF MALE-HUMAN HUMANS BY TESTOSTERONE SUPPLEMENTATION ASSOCIATED WITH 5ALPHA-REDUCTASE INHIBITOR
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
EP3045177A1 (en) * 2005-09-26 2016-07-20 The Regents of The University of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders
AU2007281381A1 (en) * 2006-08-02 2008-02-07 University Of Southern California Phytoestrogenic formulations and uses thereof
NZ595630A (en) * 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating degenerative disorders of the central nervous system
CN102397550B (zh) 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法

Also Published As

Publication number Publication date
EP3509639A1 (en) 2019-07-17
WO2018049141A1 (en) 2018-03-15
AU2017322332A1 (en) 2019-04-04
KR20190072521A (ko) 2019-06-25
CN114796236A (zh) 2022-07-29
PH12019500479A1 (en) 2019-07-29
US10300077B2 (en) 2019-05-28
BR112019004540A2 (pt) 2019-05-28
WO2018049141A4 (en) 2018-05-03
CN110177572A (zh) 2019-08-27
US20180071316A1 (en) 2018-03-15
IL265255A (en) 2019-05-30
JP2019526612A (ja) 2019-09-19
CA3036511A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
AU2016263598A8 (en) Methods and kits for treating depression
PH12018501159A1 (en) Composition and methods for immunooncology
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2018012016A (es) Compuestos biciclicos.
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12019502171A1 (en) Composition and methods for immunooncology
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12017501864A1 (en) Compositions and methods for treating autism
GB2569488A (en) PD-1 specific aptamers
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
PH12019500479A1 (en) Compositions for treating dementia
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
BR112017024855A2 (pt) métodos de produção de aldc
MX2019014861A (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion.